NYMOX Announces Submission of New Drug Application (NDA) to the FDA for Fexapotide Triflutate
March 03 2022 - 11:00AM
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is
pleased to announce today that it has submitted the Company’s New
Drug Application (NDA) to the FDA for Fexapotide Triflutate to seek
marketing approval in the U.S. for Fexapotide Triflutate for the
treatment of men with benign prostatic hyperplasia (BPH).
The submission of the application does not
involve any guarantees or forward looking statements regarding
outcomes of the submission. The Company will continue to make
updates on all material and required developments with the
application, and in accordance with prior statements provided in
the Company’s regular SEC filings.
Nymox intends to submit applications in other
major markets in the near term and will provide updates at the
appropriate times in due course.
For more information please contact
info@nymox.com or 800-936-9669.
Forward Looking Statements
To the extent that statements contained in this
press release are not descriptions of historical facts regarding
Nymox, they are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995, including statements regarding the need for new options to
treat BPH and prostate cancer, the potential of Fexapotide to treat
BPH and prostate cancer and the estimated timing of further
developments for Fexapotide. Such forward-looking statements
involve substantial risks and uncertainties that could cause our
clinical development program, future results, performance or
achievements to differ significantly from those expressed or
implied by the forward-looking statements. Such risks and
uncertainties include, among others, the uncertainties inherent in
the clinical drug development process, including the regulatory
approval process, the timing of Nymox's regulatory filings, Nymox's
substantial dependence on Fexapotide, Nymox's commercialization
plans and efforts and other matters that could affect the
availability or commercial potential of Fexapotide. Nymox
undertakes no obligation to update or revise any forward looking
statements. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to the business of Nymox in general, see Nymox's current
and future reports filed with the U.S. Securities and Exchange
Commission, including its Annual Report on Form 20-F for the year
ended December 31, 2020, and its Quarterly Reports.
For Further
Information Contact:Randall
LanhamNymox Pharmaceutical Corporation
1-800-93NYMOXwww.nymox.com
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From Sep 2023 to Sep 2024